Since inactivating mutations of TGM1 are the predominant cause of the skin disease autosomal recessive congenital ichthyosis (Pigg et al., 2016), this class of protein tyrosine phosphatase inhibitor would be inadvisable for therapeutic use in epidermis. This evidence concerns the gene TGM1 and autosomal recessive congenital ichthyosis.